Breast Cancer
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Conference Coverage
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
It’s challenging for some oncologists to keep up with the nuances of a rapidly changing field, said the author of new research.
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
Conference Coverage
Phone support helps weight loss in patients with breast cancer
After 6 months, patients who received telephone coaching and health education lost 9.7 pounds.
Conference Coverage
Breast cancer: Meta-analysis supports ovarian suppression/ablation
Controlling estrogen seems to give premenopausal women a lifespan boost, but strategy remains uncommon.
From the Journals
Lack of paid sick leave is a barrier to cancer screening
For those with paid sick leave mandates, screening rates are higher.
Conference Coverage
Circulating tumor DNA may predict poor prognosis in breast cancer
Detection of ctDNA at any time point was associated with worse overall and disease-free survival in early breast cancer patients.
Conference Coverage
Breast cancer survivors need a comprehensive care plan, says doctor
Survivor care for cancer patients should address physical and psychological symptoms through an integrated model, expert says.
Conference Coverage
Genomic assay changes minds on HER2+ BC treatment
In a small study, 56% of oncologists revised plans after getting results of HER2DX tests.
Conference Coverage
Atezolizumab is associated with enhanced response in triple-negative breast cancer
The addition of atezolizumab to chemotherapy yielded higher pCR than chemotherapy alone.